[1] Thompson SG, Higgins JPT. Can meta-analysis help target interventions at individuals most likely to benefit[J]. The Lancet,2005,365(9456) : 341-346. [2]孙 鑫,王莉,李幼平.使用个体病例数据进行Meta分析评价医疗干预措施的效果[J]. 中国循证医学, 2010, 10(8): 998-1003. [3] Advanced Ovarian Cancer Trialists Group. Chemotherapy in advanced ovarian cancer: An overview of randomised clinical trials[J].BMJ,1991,303: 884-893. [4] Abo-Zaid G, Sauerbrei W, Riley RD. Individual participant data meta-analysis of prognostic factor studies: State of the art[J].BMC,2012,12: 56. [5] Riley RD, Lambert PC, Abo-Zaid G. Meta-analysis of individual participant data: Rationale, conduct, and reporting [J]. BMJ,2010,340: c221. [6]张天嵩,钟文昭,李博.实用循证医学方法学(第二版)[M].中南大学出版社,2014,长沙. [7] Huang Y, Mao C, Yuan J, et al. Distribution and Epidemiological Characteristics of Published Individual Patient Data Meta- Analyses. PLoS ONE,2014, 9(6): e100151. [8] Stewart LA, Clarke M, Rovers M,et al. Preferred Reporting Items for Systematic Review and Meta-Analyses of individual participant data: the PRISMA-IPD Statement[J]. JAMA, 2015,313(16):1657-1665.
|